author-photo

Janet Kunsman

Harvard University

17

Papers

459

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

2013 Blood
Show All
- Source
- Cite
- Save
Citations (13)
A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

2013 Blood
Show All
- Source
- Cite
- Save
Citations (47)
Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

2011 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

2011 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (73)
Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom9s Macroglobulinemia

2011 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

2010 Blood
Show All
- Source
- Cite
- Save
Citations (11)
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (125)
Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

2010 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM).

2009 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom9s Macroglobulinemia.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (2)